- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Relapsing-remitting multiple sclerosis (RRMS)
- Meeting Date: March 2020
- Public Summary Document (PSD) March 2020 PBAC Meeting - (PDF 831KB)
- Public Summary Document (PSD) March 2020 PBAC Meeting - (Word 167KB)
Ozanimod – March 2020
Ozanimod: Capsule 230 micrograms, 460 micrograms and 920 micrograms; Zeposia®
Last updated
23 July 2020